(NASDAQ: NERV) Minerva Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Minerva Neurosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NERV's revenue for 2026 to be $138,189,703, with the lowest NERV revenue forecast at $138,189,703, and the highest NERV revenue forecast at $138,189,703. On average, 1 Wall Street analysts forecast NERV's revenue for 2027 to be $859,629,466, with the lowest NERV revenue forecast at $859,629,466, and the highest NERV revenue forecast at $859,629,466.
In 2028, NERV is forecast to generate $1,604,706,941 in revenue, with the lowest revenue forecast at $1,604,706,941 and the highest revenue forecast at $1,604,706,941.